Pfizer Seeks To Salvage Sutent For Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Company hopes development in patient subsets will save expansion plans for top-selling cancer drug.
You may also be interested in...
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.
Crizotinib Holds Promise For Lung Cancer, And For Pfizer Oncology
The targeted ALK inhibitor is on an accelerated track, with initial Phase I unveiled at ASCO annual meeting and a registration program already under way.